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Abstract  
Subclinical hypothyroidism represents a state with increased values of thyroid stimulating hormone (TSH) and 
normal values of thyroxine (T4) and triiodothyronine (T3). The disorder is asymptomatic, and the diagnosis is 
made based on the results of laboratory findings when the level of TSH reaches values above 4.0 mU/l. It is still 
subject to debate whether patients with subclinical hypothyroidism are at increased risk of cardiovascular disease, 
neuropsychiatric and neuromuscular disorders. Studies have shown that the appearance of general symptoms 
and complications are more common in patients whose values of TSH are above 10 mU/l. Therefore, the initiation 
of therapy with levothyroxine, which is the foundation of substitution therapy, is advised in patients whose TSH is 
>10 mU/l. As for patients whose values of TSH are from 4.0 to 10.0 mU/l and who make up 90% of the patients 
with subclinical hypothyroidism, further research is needed to determine the effects of the disorder and 
levothyroxine therapy on the health. Until then, the introduction of the substitution therapy in patients with TSH 
which is <10 mU/l should be considered in the case of the presence of general symptoms, anti-thyroid antibodies, 
increased lipids and other risk factors, goitre, pregnancy, ovarian dysfunction and infertility. 
 
 
 
 
 
Introduction 
 
Subclinical hypothyroidism (SH) is a very 
common disorder in the general population, especially 
among middle-aged and elderly patients. It represents 
a state with increased values of thyroid stimulating 
hormone (TSH) and normal values of thyroxine (T4) 
and triiodothyronine (T3) [1]. In most cases, patients 
with SH have no symptoms that would indicate this 
disorder, so diagnosis is made based on laboratory 
findings [2]. As the values of thyroid hormone are 
normal, increased level of TSH represents a 
compensatory mechanism that stimulates the thyroid 
gland to produce sufficient amounts of thyroid 
hormones. The disorder can eventually progress to 
overt hypothyroidism (OH) which is characterised by 
increased values of TSH but reduced values of thyroid 
hormones [3]. Since the SH is asymptomatic disorder 
in which the values of thyroid hormones are normal, 
and it may be a prelude to a clinically manifest 
disease of the thyroid gland, the question is whether it 
should be treated. This paper aims to summarize the 
available data on the influence of this disorder on the 
health of patients, as well as data on the effects of 
treatment to answer the question whether SH should 
be treated and if so when to start the treatment. 
 
 
Subclinical hypothyroidism and clinical 
significance 
 
Clinically OH and decreased production of the 
thyroid hormones is associated with an increased 
cardiovascular risk [4], but what about the SH where 
Review Article 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
  2                                                                                                                                                                                                                         http://www.mjms.mk/ 
http://www.id-press.eu/mjms/ 
 
the values of the thyroid hormones are still normal?  
Values of TSH above 4.0 mU/l represent 
increased levels and by their increase the SH can be 
divided into a mild form (values from 4.0-10.0 mU/l) 
and a more severe form (values >10.0 mU/l). As long 
as the values of this hormone are over the limit, levels 
of thyroid hormones are not sufficient to provide the 
euthyroid state. If it weren't so, we would expect the 
value of TSH, whose half-life is 1h, to drop to normal 
values as soon as T4 and T3, whose half-life is seven 
days and 1 day, reach normal values. However, this 
does not happen in SH because the values of TSH 
remain increased even when T4 and T3 reach normal 
values [3]. 
SH is usually asymptomatic, but in some 
patients may still appear symptoms that would 
indicate hypothyroidism. In the US Colorado Thyroid 
Disease Prevalence Study, which included 20,862 
examinees, patients with SH more frequently reported 
symptoms compared to euthyroid examinees but less 
frequently than patients with OH. The most common 
symptoms were dry skin, poor memory, slower 
thinking, weakness and muscle cramps, swollen face 
with periorbital oedema, fatigue, hoarseness, deep 
voice and constipation. The same study showed that 
in the majority of patients (74%) with SH the levels of 
TSH were between 5.1-10.0 mU/l, while in 26% were 
above ten mU/l [5]. This means that most of these 
patients have mainly a slight disturbance of the 
function of the thyroid gland which is the case in 90% 
of patients with SH in general population [6].  
Although the appearance of these symptoms 
could mean that this disorder could have 
consequences for the health of patients, there is still 
no evidence for possible harmful effects on 
individual's health. Besides the ability to progress to 
clinically OH, some studies have shown that SH could 
be associated with increased risk of cardiovascular 
disease (CVD), mood disorders and cognitive 
dysfunction as well as impaired neuromuscular 
function [2, 3, 6, 7].  
 
 
Subclinical hypothyroidism and 
cardiovascular system 
 
Thyroid hormones exert a direct influence on 
the heart and blood vessels. The deficit of these 
hormones leads to functional disorders of the CVS, so 
changes in cardiac frequency, cardiac output and 
systemic vascular resistance are closely related to the 
thyroid status [8, 9]. 
In SH there is a disruption of the systolic and 
diastolic function of the left ventricle. In the blood 
vessels, there are also changes in the form of 
increased vascular resistance, increased arterial 
stiffness and endothelial dysfunction [6]. 
Thyroid hormones also influence the lipid 
status. Many studies have shown that patients with 
SH have increased the level of total cholesterol, as 
well as low-density lipoprotein (LDL) about the 
euthyroid patients [5, 10]. Despite these results, a 
clear connection between lipids and SH has not been 
established because some studies have shown that 
the lipid profiles of patients with SH were not 
significantly different compared to euthyroid patients 
[11]. However, the lipid profile was more impaired in 
patients whose TSH is >10 mU/l and in smokers [12]. 
Patients with SH are also believed to be at increased 
risk of atherosclerosis. That is shown in Rotterdam 
study that examined the connection between the 
atherosclerotic process and SH in 1,149 women aged 
over 55 years. In this study, patients with TSH >4 mU/l 
had an increased risk of atherosclerosis and 
occurrence of myocardial infarction [13]. 
Disturbed blood coagulation is also seen in 
patients with SH. The values of some coagulation 
factors are increased, and the whole fibrinolytic 
activity is decreased which might result in increased 
blood coagulation [12]. Bearing in mind the potential 
influence on the structure and function of the CV 
system and lipid status, Rodondi et al. examined 
2,730 patients between 70 and 79 years, of whom 338 
had SH, to investigate their risk of CV morbidity and 
mortality. They have shown that in patients with TSH 
levels ≥ 7, there was an increased risk of chronic 
heart failure in comparison to other euthyroid patients, 
but there was no increased risk of other CV events 
and mortality. In examinees whose TSH values were 
between 4.5 and 6.9 mU/l an increased risk of CV 
morbidity and mortality has not been observed 
compared to euthyroid examinees [14]. The same 
author's analysis of 11 prospective studies that 
included 55,287 examinees showed that increase in 
levels of TSH increases the risk of CV events and CV 
mortality, especially among those whose TSH is >10 
mU/l. The disadvantage in interpreting these results 
lies in the fact that some of these studies involved 
patients with the prior existence of CV disease [15, 
16]. 
Due to the extreme heterogeneity of the 
studies, we cannot make accurate conclusions about 
the influence of SH on CV system, although we can 
conclude that there is no evidence that a mild form of 
SH (TSH values are from 4.0 to 10.0 mU/l) may have 
consequences for patient's CV system. 
 
 
Subclinical hypothyroidism, mood and 
cognitive functions  
 
Some, but not all studies have shown the 
connection between anxiety and depressive disorders 
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with SH [17, 18]. In middle-aged patients with SH was 
observed the more frequent occurrence of depression 
and the occurrence of severe forms of depressive 
disorders compared to euthyroid examinees. 
Although the deficit of thyroid hormones leads 
to disorder of affective and cognitive functions, the 
influence of SH on these functions is not yet fully 
understood. Given that in most cases the SH is 
caused by autoimmune process and associated with 
an increased titer of antibodies to thyroid peroxidase 
(TPO) and thyroglobulin, it should be noted that the 
presence of these antibodies can cause cerebral 
dysfunction known as Hashimoto encephalopathy [8]. 
 
 
Subclinical hypothyroidism and 
neuromuscular function 
 
The exact mechanism that would be placed 
by disorders of neuromuscular function is not fully 
understood, but it is thought that disorder in glycogen 
lysis, expression of heavy chains of myosin and the 
mitochondrial activity could be the reason for the 
appearance of these symptoms in patients with SH. 
One study examined 12 patients with SH who 
complained of neuromuscular ailments during rest and 
exercise. The amount of created lactates and 
pyruvates in skeletal muscles during exercise were 
significantly higher in patients with SH in comparison 
to the control group. Based on the results, it can be 
concluded that energy metabolism of muscles may be 
disturbed in patients with SH [12]. 
 
 
Subclinical hypothyroidism and the 
progression to clinical hypothyroidism 
 
SH is a disorder that occurs more frequently 
in women, the elderly and in areas where there is an 
increased intake of iodine. Prevalence rate ranges 
from 4 to 10% in the adult population, and if there is 
an increased intake of iodine, it is up to 24% [12, 19]. 
In 80% of patients with SH, there is an increased titer 
of anti-thyroid antibodies, which means that in most 
cases an autoimmune process is present [7]. 
The clinical course of SH can move in the 
direction of development of OH, as well as in the 
direction of normalisation of values of TSH. One of the 
prospective studies followed the clinical course in 82 
women who had increased values of TSH and 
showed that after a period of 10 years, 28% of them 
developed OH (TSH > 20 mU/l and decreased levels 
of free T4), 68% of them still had a subclinical 
disorder, while 4% of them reached the normalization 
of TSH levels [20]. 
Diez et al. examined the natural course of SH 
in 107 patients and have shown that patients with mild 
SH disorder (TSH levels from 5.0 to 9.9 mU/l) have 
more chances to have values of TSH normalised 
compared to patients whose TSH is > 10.0 mU/l. It 
was also shown that the value of TSH was the most 
important prognostic factor for the outcome of SH [21]. 
 
 
The effects of the treatment of patients 
with subclinical hypothyroidism 
 
Studies that dealt with the effects of therapy 
often researched its influence on the disorder of the 
lipid profile of patients, as a possible significant risk for 
future CV disease. In the report of the working group 
of the United States for the prevention (U.S. 
Preventive Services Task Force - USPSTF), seven 
studies examined the influence of treatment of SH on 
the values of lipids. Six of them showed that the 
treatment of SH does not lead to improvement in lipid 
parameters [16]. 
On the other hand, an analysis of 13 studies 
and a total of 247 examinees showed different results. 
All patients had a disorder of TSH levels, no matter if 
they had spontaneous SH or OH with an insufficient 
dose of levothyroxine to normalise the value of TSH. 
The mean value of TSH at the beginning was 10.8 
mU/l, and after the treatment period (12 weeks to 3 
months) it was 2.6 mU/l. In 11 out of 13 studies there 
has been a decrease in the value of total cholesterol (-
0.20 mmol/L (-7.9 mg/dL, or 5%)) and 7 out of 9 there 
has been a decrease in the value of LDL (-0.26 
mmol/L (-10 mg/dL)). Changes in values of HDL and 
triglycerides were not statistically significant.  
However, most of these studies included small 
samples, most of them were not randomised and did 
not include a control group [22].  
Since it is known that thyroid hormones 
perform a substantial effect on the heart, some 
studies have examined the influence of levothyroxine 
therapy on the structure and function of the heart in 
patients with SH. One such, double-blind and 
placebo-controlled study was conducted by Monzani 
et al. and it showed that patients with SH had a 
disorder in systolic and diastolic function of the left 
ventricle and that the levothyroxine therapy led to 
complete regression of it [23]. 
Great retrospective study based on data from 
the Danish National Patient Registry has examined 
the influence of levothyroxine therapy in patients with 
SH on the risk of myocardial infarction, as well as 
cardiovascular and total mortality. No effect was seen 
on the risk of myocardial infraction or the CV mortality. 
As for total mortality, the results showed that patients 
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younger than 65 years could have some marginal 
benefit [24]. 
Substitution therapy had different effects 
regarding cognitive functions which may be because 
SH is not a disorder that leads to global cognitive 
dysfunction and its numerous domains, but the more 
subtle changes in specific domains such as memory 
and executive functions of the brain [25]. 
As for mood disorders, although there is 
evidence that in patients with affective disorders often 
occurs SH, there is no evidence that substitution 
therapy has favourable effects [8, 26]. 
Levothyroxine therapy can lead to a reduction 
and the complete disappearance of the present 
antibodies in hypothyroid patients with Hashimoto 
thyroiditis. Still, there is no clear evidence that the 
early initiation of therapy might affect the spontaneous 
course of SH [1, 12, 27].  
 
 
The negative effects of therapy 
 
The most common negative consequence of 
levothyroxine therapy is the occurrence of subclinical 
hyperthyroidism and in some cases occurrence of 
iatrogenic hyperthyroidism [2, 27, 28]. Between 10% 
and 33% of patients who take levothyroxine have 
values of TSH below normal, and in more than half of 
these patients, TSH is less than 0.1 m/L [27]. 
Other adverse effects are related to the effect 
of levothyroxine on the bones and heart. Studies that 
examined the effect of TSH suppression by 
levothyroxine on bone density did not provide specific 
conclusions whether the therapy could lead to an 
increased risk of osteoporosis [26, 27]. As for the 
effects on the heart, subclinical hyperthyroidism in 
people older than 60 years is associated with 
increased 10-year risk of developing atrial fibrillation 
[26]. 
 
 
Whether and when to start treatment? 
 
SH is considered to be a mild disorder which 
can have consequences for the health and 
introduction of substitution therapy may be beneficial 
in some patients. Most of these patients have values 
of TSH from 4.0 to 10.0 mU/l and minimal metabolic 
and physiological disorders. Therefore, starting 
substitution therapy in these patients isn't usually 
justified. They should be rather monitored and 
controlled every 6 to 12 months [7, 12, 27]. Therapy 
should be considered if there are present antibodies 
on TPO, general symptoms that are suggestive of 
hypothyroidism, increased values of total and LDL 
cholesterol, nodular or diffuse enlargement of the 
thyroid gland, pregnancy or ovulatory dysfunction with 
infertility [12, 17]. 
The results of many studies have shown that 
treatment with substitution therapy should be initiated 
in patients with TSH values above ten mU/l because 
these patients are at increased risk of developing 
health disorders (dyslipidemia, CV events, psychiatric, 
neuromuscular disorders, and occurrence of general 
symptoms). Although there isn't enough evidence that 
levothyroxine therapy could lower the values of total 
and LDL cholesterol, it's beneficial effects cannot be 
excluded. Clinicians are advised to decide on a case-
by-case basis, particularly if patients are smokers and 
have other risk factors for cardiovascular disease 
(hypertension, insulin resistance and diabetes, renal 
failure, etc.) [27, 29]. 
High values of TSH also increase the risk of 
developing clinically OH. There is no evidence that 
treatment will postpone the progression of the 
disorder, but perhaps it could help coping with 
symptoms [30]. One of the strongest reasons why the 
treatment is proposed when TSH reaches values 
above 10.0 mU/l is that the favourable results of 
substitution therapy are more obvious in these 
patients [2, 6, 7, 12, 29, 30]. 
Treatment is initiated with levothyroxine. 
Usual doses 25-75 mg/day are sufficient to normalise 
levels of TSH in patients with SH. Doses should be 
carefully titrated until TSH reaches value between 1 
and 2-3 mU/l in younger and middle-aged patients. 
When the optimum values are reached, TSH should 
be controlled every 6-12 months [12].  
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